Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension

Journal of Clinical Pharmacology

Volumn 36, Issue 5, 1996, Pages 403-408

  Sasaki, Masato ^a   Fujimura, Akio ^a   Harada, Kazuhiro ^a   Sunaga, Ken Ichiro ^a   Ebihara, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; URIC ACID;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SINGLE BLIND PROCEDURE;

EID: 0029993083     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb05026.x     Document Type: Article

References (12)

1. Duncia JV, Carini DJ, Chin AT, Johnson AL, Price WA, Wong PC, et al: The discovery of DuP753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992;12:149-191.
2. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
3. Wong PC, Price WA, Chin AT, Duncia JV, Carini DJ, Wexler RR, et al: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;255: 211-217.
4. Nakashima M, Uematsu T, Kosuge K, Kanamaru M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-335.
5. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993;35:290-297.
6. Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A: Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone. J Clin Pharmacol 1995;35:776-779
7. Brown BW, Hollander M: Statistics. A Biomedical Introduction New York: John Wiley & Sons, 1977.
8. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, et al: Oral administration of DuP753, a specific angiotensin receptor antagonist, to normal male volunteers. Circulation 1991;83:1333-1342.
9. Munafo A, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, et al: Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992;51:513-521.
10. Timmermans PBMWM, Benfield P, Chin AT, Herblin WF, Wong PC, Smith RD: Angiotensin II receptors and functional correlates. Am J Hypertens 1992;5:2215-2355.
11. Burnier M, Rutshmann B, Nussberger J, Versaggl J, Shahinfar S, Weaber B, Brunner HR: Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22: 339-347.
12. Cannon PJ, Stason WB, Demartinin FE, Sommers SC, Laragh JH: Hyperuricemia in primary and renal hypertension. N Engl J Med 1966;275:457-464.